Hainan Huluwa Pharmaceutical Group Co Ltd (605199) - Total Assets

Latest as of March 2026: CN¥2.56 Billion CNY ≈ $374.03 Million USD

Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) holds total assets worth CN¥2.56 Billion CNY (≈ $374.03 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Hainan Huluwa Pharmaceutical Group Co Ltd - Total Assets Trend (2016–2025)

This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Hainan Huluwa Pharmaceutical Group Co Lt market cap and net worth for the company's overall valuation and market capitalisation.

Hainan Huluwa Pharmaceutical Group Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Hainan Huluwa Pharmaceutical Group Co Ltd's total assets of CN¥2.56 Billion consist of 33.9% current assets and 66.1% non-current assets. Review 605199 total debt and obligations to assess the company's total debt and financial obligations.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 3.0%
Accounts Receivable CN¥418.01 Million 16.1%
Inventory CN¥254.34 Million 9.8%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥274.49 Million 10.6%
Goodwill CN¥0.00 0.0%

Asset Composition Trend (2016–2025)

This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Hainan Huluwa Pharmaceutical Group Co Lt stock price for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Hainan Huluwa Pharmaceutical Group Co Ltd's current assets represent 33.9% of total assets in 2025, a decrease from 41.1% in 2016.
  • Cash Position: Cash and equivalents constituted 3.0% of total assets in 2025, down from 11.6% in 2016.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 20.0% in 2016.
  • Asset Diversification: The largest asset category is accounts receivable at 16.1% of total assets.

Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Total Assets

Key competitors of Hainan Huluwa Pharmaceutical Group Co Ltd based on total assets are shown below.

Company Country Total Assets
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
India Rs443.12 Billion
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Sweden Skr81.26 Billion
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Germany €1.60 Trillion
Beijing Tongrentang Co Ltd
SHG:600085
China CN¥29.95 Billion
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
China CN¥19.57 Billion
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
China CN¥12.75 Billion
Harbin Pharmaceutical Group Co Ltd
SHG:600664
China CN¥14.08 Billion
Kangmei Pharmaceutical Co Ltd
SHG:600518
China CN¥13.68 Billion

Hainan Huluwa Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.63 0.84 2.22
Quick Ratio 0.46 0.53 1.69
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥-510.46 Million CN¥-232.47 Million CN¥434.27 Million

Hainan Huluwa Pharmaceutical Group Co Ltd - Advanced Valuation Insights

This section examines the relationship between Hainan Huluwa Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 6.97
Latest Market Cap to Assets Ratio 0.13
Asset Growth Rate (YoY) -12.2%
Total Assets CN¥2.60 Billion
Market Capitalization $340.75 Million USD

Valuation Analysis

Below Book Valuation: The market values Hainan Huluwa Pharmaceutical Group Co Ltd's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Hainan Huluwa Pharmaceutical Group Co Ltd's assets decreased by 12.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)

The table below shows the annual total assets of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025.

Year Total Assets Change
2025-12-31 CN¥2.60 Billion
≈ $380.89 Million
-12.20%
2024-12-31 CN¥2.96 Billion
≈ $433.81 Million
-3.14%
2023-12-31 CN¥3.06 Billion
≈ $447.85 Million
+32.37%
2022-12-31 CN¥2.31 Billion
≈ $338.33 Million
+31.30%
2021-12-31 CN¥1.76 Billion
≈ $257.68 Million
+15.76%
2020-12-31 CN¥1.52 Billion
≈ $222.59 Million
+39.99%
2019-12-31 CN¥1.09 Billion
≈ $159.00 Million
-0.49%
2018-12-31 CN¥1.09 Billion
≈ $159.79 Million
+35.28%
2017-12-31 CN¥807.21 Million
≈ $118.12 Million
+50.61%
2016-12-31 CN¥535.95 Million
≈ $78.43 Million
--

About Hainan Huluwa Pharmaceutical Group Co Ltd

SHG:605199 China Drug Manufacturers - Specialty & Generic
Market Cap
$340.75 Million
CN¥2.33 Billion CNY
Market Cap Rank
#14377 Global
#4323 in China
Share Price
CN¥5.82
Change (1 day)
-0.68%
52-Week Range
CN¥5.19 - CN¥10.20
All Time High
CN¥48.21
About

Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceut… Read more